Abstract 2255P
Background
The recent development of direct KRAS inhibitors has changed the treatment landscape of patients (pts) with oncogenic KRAS mutations. However, whether KRAS amplification (KRASAMP) also defines a unique subset of cancers and represents a potential target for drug development is unknown.
Methods
Clinicogenomic data and outcomes were abstracted from independent cohorts of human cancers with genomic profiling at the Dana-Farber Cancer Institute, AACR-GENIE v.13, The Cancer Genome Atlas (TCGA), and 212 other studies, and examined according to KRASAMP status. We also correlated KRASAMP with KRAS RNA and protein expression using whole transcriptome and proteomics data from the TCGA and the Cancer Cell Lines Encyclopedia.
Results
Among 103,523 pts with solid and hematologic cancers, KRASAMP was identified in 1,744 (1.7%) of cases. KRASAMP was most prevalent in germ cell tumors (16.3%), esophagogastric (7.5%), ovarian (4.2%), pancreatic (2.2%), breast (2%), colorectal (CRC, 1.2%), and non-small cell lung cancer (NSCLC, 1.2%). Among these pts, median age was 61, 61.5% were ever smokers, 85.4% were white, and 71.8% had poorly differentiated cancers. Compared to KRAS diploid cases, KRASAMP cancers had a higher fraction of the genome altered (p<0.01). Microsatellite instability scores were also higher in KRASAMP tumors from patients with breast, esophagogastric, germ cell, pancreatic and NSCLC (p<0.01), but not in CRC (p=0.22). Tumor mutational burden was higher (p<0.01) among CRC, NSCLC, and esophagogastric cancers with KRASAMP vs KRAS diploid. Compared to KRAS diploid samples, KRASAMP samples had increased KRAS mRNA (p<0.01) and protein expression (p<0.01). Among pts with clinical outcome data (N=41,900), median overall survival (OS) was shorter in all comers with KRASAMP vs KRAS diploid genotype (adjusted HR 1.68, p<0.01), and in each cancer type analyzed separately. KRASAMP conferred worse survival outcomes in pts with both KRAS wild-type (N=35,599, adjusted HR 1.38, p=0.01) and KRAS-mutant (N=6,301, adjusted HR 1.70, p<0.01) cancers.
Conclusions
KRAS amplification defines a novel subset of human cancers characterized by distinct genomic features, and worse survival. Novel therapeutic strategies to target KRASAMP may improve outcomes in pts with cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Biagio Ricciuti.
Funding
Has not received any funding.
Disclosure
B. Ricciuti: Financial Interests, Personal, Advisory Board: Regeneron. P.A. Jänne: Financial Interests, Personal, Advisory Board, Consulting fees for advice on drug development: AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly, Voronoi, Daiichi Sankyo, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Trasncenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Eisai, Allorion Therapeutics, Accutar Biotech, AbbVie, Duality Biologics; Financial Interests, Personal, Advisory Board, Consulting fees for advice on diagnostic development: Biocartis; Financial Interests, Personal, Advisory Board, Consulting fee for advice on drug development: Merus, Frontier Medicines; Financial Interests, Personal, Advisory Board, Consulting fees for advice on drug development: Hongyun Biotechnology; Financial Interests, Personal, Stocks/Shares: Gatekeeper Pharmaceuticals, Allorion Therapeutics; Financial Interests, Personal, Royalties, I receive post-marketing royalties from being an inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp: Lab Corp; Financial Interests, Institutional, Research Grant, Sponsored research agreement with my institution: AstraZeneca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim, Revolution Medicines, Takeda Oncology. M.M. Awad: Financial Interests, Personal, Advisory Board: Merk, BMS, AZ, Genentech, Nekter, Maverick, Blueprint Medicine, AbbVie, Gritstone, ArcherDX, Mirati; Financial Interests, Advisory Board: NextCure. All other authors have declared no conflicts of interest.
Resources from the same session
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08
2283P - Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Presenter: Benjamin Schoeps
Session: Poster session 08